Terrebonne, A. | bioRxiv Science

bioRxiv2026

Coordinated topoisomerase function shapes the fluoroquinolone response of Chlamydia trachomatis

DNA supercoiling is essential for the developmental cycle of Chlamydia trachomatis, yet its role in shaping antibiotic responses remains poorly understood. We investigated how the fluoroquinolone moxifloxacin (Mox) influenced C. trachomatis growth across developmental stages with its distinct supercoiling levels. Early Mox exposure completely halted bacterial growth, whereas treatment during mid-cycle produced enlarged, persistent forms and abolished formation of infectious progeny. These stage-specific outcomes coincided with inhibition of DNA replication, depletion of DNA gyrase, and transcriptional repression of ompA and omcB, accompanied by preserved or elevated expression of the stress-responsive groESL1 operon. Mox also elicited compensatory downregulation of topoisomerase I (TopA), consistent with attempts to rebalance intracellular supercoiling. Together, these data demonstrate that fluoroquinolone susceptibility in C. trachomatis reflects stage-dependent supercoiling levels. Perturbation of supercoiling homeostasis drives developmental arrest and persistence phenotypes, highlighting coordinated gyrase-TopA activity as a key determinant of fluoroquinolone tolerance and a potential target for overcoming persistent infection. ImportanceC. trachomatis, a medically significant bacterial pathogen, can persist under antimicrobial pressure, complicating treatment strategy. This study links supercoiling homeostasis to fluoroquinolone tolerance, offering mechanistic insights into chlamydial adaptation to antibiotic stress and identifying potential targets to overcome persistence--an urgent challenge in global reproductive health.

microbiology↗

bioRxiv2024

The SWIB domain-containing DNA topoisomerase I of Chlamydia trachomatis mediates DNA relaxation

The obligate intracellular bacterial pathogen, Chlamydia trachomatis (Ct), has a distinct DNA topoisomerase I (TopA) with a C-terminal domain (CTD) homologous to eukaryotic SWIB domains. Despite the lack of sequence similarity at the CTDs between C. trachomatis TopA (CtTopA) and Escherichia coli TopA (EcTopA), full-length CtTopA removed negative DNA supercoils in vitro and complemented the growth defect of an E. coli topA mutant. We demonstrated that CtTopA is less processive in DNA relaxation than EcTopA in dose-response and time course studies. An antibody generated against the SWIB domain of CtTopA specifically recognized CtTopA but not EcTopA or Mycobacterium tuberculosis TopA (MtTopA), consistent with the sequence differences in their CTDs. The endogenous CtTopA protein is expressed at a relatively high level during the middle and late developmental stages of C. trachomatis. Conditional knockdown of topA expression using CRISPRi in C. trachomatis resulted in not only a developmental defect but also in the downregulation of genes linked to nucleotide acquisition from the host cells. Because SWIB-containing proteins are not found in prokaryotes beyond Chlamydia spp., these results imply a significant function for the SWIB-containing CtTopA in facilitating the energy metabolism of C. trachomatis for its unique intracellular growth. ImportanceC. trachomatis (Ct) is a medically important bacterial pathogen that is responsible for the most prevalent sexually transmitted bacterial infection. Bioinformatics, genetics, and biochemical analyses have established that the presence of a SWIB domain in CtTopA, a DNA topoisomerase I, is relevant to chlamydial physiology. Further defining the mechanisms of the C-terminal SWIB domain on the catalytic function of CtTopA in an intracellular pathogen is warranted for a more complete understanding of the interactions between C. trachomatis and its host cells.

molecular biology↗